Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

64 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor.
Sebestyen Z, Scheper W, Vyborova A, Gu S, Rychnavska Z, Schiffler M, Cleven A, Chéneau C, van Noorden M, Peigné CM, Olive D, Lebbink RJ, Oostvogels R, Mutis T, Schuurhuis GJ, Adams EJ, Scotet E, Kuball J. Sebestyen Z, et al. Cell Rep. 2016 May 31;15(9):1973-85. doi: 10.1016/j.celrep.2016.04.081. Epub 2016 May 19. Cell Rep. 2016. PMID: 27210746 Free PMC article.
Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.
de Bruin RC, Stam AG, Vangone A, van Bergen En Henegouwen PM, Verheul HM, Sebestyén Z, Kuball J, Bonvin AM, de Gruijl TD, van der Vliet HJ. de Bruin RC, et al. Among authors: sebestyen z. J Immunol. 2017 Jan 1;198(1):308-317. doi: 10.4049/jimmunol.1600948. Epub 2016 Nov 28. J Immunol. 2017. PMID: 27895170
GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR.
Straetemans T, Kierkels GJJ, Doorn R, Jansen K, Heijhuurs S, Dos Santos JM, van Muyden ADD, Vie H, Clemenceau B, Raymakers R, de Witte M, Sebestyén Z, Kuball J. Straetemans T, et al. Among authors: sebestyen z. Front Immunol. 2018 May 30;9:1062. doi: 10.3389/fimmu.2018.01062. eCollection 2018. Front Immunol. 2018. PMID: 29899740 Free PMC article.
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.
de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, Stam AG, Sebestyen Z, Kuball J, Molthoff CFM, Hooijberg E, Roovers RC, Santo JPD, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ. de Bruin RCG, et al. Among authors: sebestyen z. Oncoimmunology. 2017 Oct 20;7(1):e1375641. doi: 10.1080/2162402X.2017.1375641. eCollection 2017. Oncoimmunology. 2017. PMID: 29296532 Free PMC article.
Cancer Immunotherapy Using γδT Cells: Dealing with Diversity.
Scheper W, Sebestyen Z, Kuball J. Scheper W, et al. Among authors: sebestyen z. Front Immunol. 2014 Nov 20;5:601. doi: 10.3389/fimmu.2014.00601. eCollection 2014. Front Immunol. 2014. PMID: 25477886 Free PMC article. Review.
Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer.
Straetemans T, Gründer C, Heijhuurs S, Hol S, Slaper-Cortenbach I, Bönig H, Sebestyen Z, Kuball J. Straetemans T, et al. Among authors: sebestyen z. Clin Cancer Res. 2015 Sep 1;21(17):3957-68. doi: 10.1158/1078-0432.CCR-14-2860. Epub 2015 May 19. Clin Cancer Res. 2015. PMID: 25991821
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Drent E, Groen RW, Noort WA, Themeli M, Lammerts van Bueren JJ, Parren PW, Kuball J, Sebestyen Z, Yuan H, de Bruijn J, van de Donk NW, Martens AC, Lokhorst HM, Mutis T. Drent E, et al. Among authors: sebestyen z. Haematologica. 2016 May;101(5):616-25. doi: 10.3324/haematol.2015.137620. Epub 2016 Feb 8. Haematologica. 2016. PMID: 26858358 Free PMC article.
64 results